Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes

McIlvride, Saraid, Nikolova, Vanya, Fan, Hei Man, McDonald, Julie A. K., Wahlström, Annika, Bellafante, Elena, Jansen, Eugene, Adorini, Luciano, Shapiro, David, Jones, Peter, Marchesi, Julian R., Marschall, Hanns-Ulrich and Williamson, Catherine 2019. Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes. AJP - Endocrinology and Metabolism 317 (2) , E399-E410. 10.1152/ajpendo.00407.2018

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (420kB) | Preview

Abstract

Metabolism alters markedly with advancing gestation, characterized by progressive insulin resistance, dyslipidemia, and raised serum bile acids. The nuclear receptor farnesoid X receptor (FXR) has an integral role in bile acid homeostasis and modulates glucose and lipid metabolism. FXR is known to be functionally suppressed in pregnancy. The FXR agonist, obeticholic acid (OCA), improves insulin sensitivity in patients with type 2 diabetes with nonalcoholic fatty liver disease. We therefore hypothesized that OCA treatment during pregnancy could improve disease severity in a mouse model of gestational diabetes mellitus (GDM). C57BL/6J mice were fed a high-fat diet (HFD; 60% kcal from fat) for 4 wk before and throughout pregnancy to induce GDM. The impact of the diet supplemented with 0.03% OCA throughout pregnancy was studied. Pregnant HFD-fed mice displayed insulin resistance and dyslipidemia. OCA significantly reduced plasma cholesterol concentrations in nonpregnant and pregnant HFD-fed mice (by 22.4%, P < 0.05 and 36.4%, P < 0.001, respectively) and reduced the impact of pregnancy on insulin resistance but did not change glucose tolerance. In nonpregnant HFD-fed mice, OCA ameliorated weight gain, reduced mRNA expression of inflammatory markers in white adipose tissue, and reduced plasma glucagon-like peptide 1 concentrations (by 62.7%, P < 0.01). However, these effects were not evident in pregnant mice. OCA administration can normalize plasma cholesterol levels in a mouse model of GDM. However, the absence of several of the effects of OCA in pregnant mice indicates that the agonistic action of OCA is not sufficient to overcome many metabolic consequences of the pregnancy-associated reduction in FXR activity.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
Publisher: American Physiological Society
ISSN: 0193-1849
Date of First Compliant Deposit: 9 October 2019
Date of Acceptance: 18 June 2019
Last Modified: 01 Jun 2020 09:14
URI: http://orca.cf.ac.uk/id/eprint/125931

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics